Theratechnologies inc.

Theratechnologies inc.

November 26, 2007 16:50 ET

Theratechnologies to Present at Lazard Capital Markets Fourth Annual Healthcare Conference in New York

MONTREAL, QUEBEC--(Marketwire - Nov. 26, 2007) - Theratechnologies (TSX:TH) announced today that Yves Rosconi, President and Chief Executive Officer, will present an overview of Theratechnologies at the Fourth Annual Healthcare Conference hosted by Lazard Capital Markets at 2:00 p.m. on Wednesday, November 28, 2007, at the Palace Hotel in New York City.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. Tesamorelin, an investigational new drug, could be the first compound on the market to treat HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information